In recent years aberrant neural oscillations in various cortical areas have emerged as a common physiological hallmark across mouse models of amyloid pathology and patients with Alzheimer's disease. However, much less is known about the underlying effect of amyloid pathology on single cell activity. Here, we used high density silicon probe recordings from frontal cortex area of 9 months old APP/PS1 mice to show that resting state Local Field Potential (LFP) power in the theta and beta band is increased in transgenic animals, while single cell firing rates, specifically of putative pyramidal cells, are significantly reduced. At the same time, these sparsely firing pyramidal cells phase-lock their spiking activity more strongly to the ongoing theta and beta rhythms. Furthermore, we demonstrated that the anti-epileptic drug, levetiracetam, can restore principal cell firing rates back to control levels. Overall, our results highlight reduced firing rates of cortical pyramidal cells as a symptom of amyloid pathology and indicate that lifting cortical inhibition might contribute to the beneficial effects of levetiracetam on AD patients.
Introduction
Network hyper-synchrony and altered neural oscillation have been suggested to contribute to the pathophysiology of Alzheimer's disease (AD). A better understanding of altered neural oscillations in AD could therefore provide a target for pharmacological interventions.
Even though amyloid plaques and related neuronal loss are among the most significant findings in the post mortem brain of AD patients, the amount of plaques does not correlate with the severity of dementia (Nagy et al., 1995) , and the removal of plaques does not lead to an improvement of memory (Holmes et al., 2008) . Intriguingly, amyloid accumulation seems to cause excitatoryinhibitory imbalance at the synaptic level, triggering abnormal patterns of single cell, as well as neuronal network activity and epileptiform discharges (Minkeviciene et al., 2009) . Simultaneously with amyloid plaque formation, both hyper-and hypoactive neurons emerge in the hippocampus but also in the cortical areas (Busche et al., 2008; Heggland et al., 2019; Xu et al., 2015) . Less is known about which subpopulations of cells are affected by amyloid accumulation but it has been proposed that this pathological process is related to persistently decreased resting membrane potential in neocortical pyramidal neurons (Minkeviciene et al., 2009) . Similarly, it has been reported that basic biophysical properties of pyramidal neurons in frontal cortex are intact but external stimulation of these neurons revealed hyper-excitability, indicating a combination of both intrinsic electrical and synaptic dysfunctions as mechanisms for activity changes (Kellner et al., 2014) .
Whether these findings apply to in vivo unanesthetized mice, needs to be verified.
On the level of neuronal assemblies, the most prominent finding related to amyloid pathology is abnormally high LFP (Local Field Potential) power over a broad frequency range during wide variety of behavioral states (Goutagny et al., 2013; Gurevicius et al., 2013; Jin et al., 2018; Pena-Ortega et al., 2012; Verret et al., 2012) , which can lead to epileptiform synchronous discharges and generalized seizure activity (Gurevicius et al., 2013; Jin et al., 2018; Lam et al., 2017; Minkeviciene et al., 2009; Palop and Mucke, 2016; Vossel et al., 2013) . The mechanism by which aberrant single cell activity changes into generalized epileptiform activity of neuronal ensembles is not clear.
Traditionally, epileptic seizures have been characterized as hypersynchrony of large neuronal populations leading to the epileptiform state (Jiruska et al., 2013) .
However, this view has been challenged by the finding that, during epileptic seizures, there are both increases and decreases in firing rates of neurons and many units remaining unchanged (Schevon et al., 2012; Truccolo et al., 2011; Wyler et al., 1982) . Furthermore, single cell activity outside the periods of seizures and areas of epileptic foci is more heterogeneous and unsynchronized, and not well characterized (Keller et al., 2010; Truccolo et al., 2011) . In addition, to our knowledge it is not known if amyloid accumulation affecting EEG power in broad frequency band is also entraining single cell activity.
In recent years, antiepileptic pharmacological treatments to balance altered neuronal activity as a consequence of amyloid accumulation have become of interest (Cumbo and Ligori, 2010; Ziyatdinova et al., 2015 Ziyatdinova et al., , 2011 . Acute dose of levetiracetam in a animal model reduces abnormal EEG spiking activity in the cortex and in the hippocampus for 18 hours after administration (Sanchez et al., 2012) .
Notably, sub-chronic treatment with levetiracetam has been shown to boost abnormal hypoactivation in the entorhinal cortex in people with amnestic mild cognitive impairment (aMCI) while simultaneously improving working memory performance (Bakker et al., 2012) .
Currently, this treatment is under clinical testing although the basic mechanisms of action of levetiracetam in AD patients is not well understood (Bakker et al., 2015) .
In animal models overexpressing amyloid protein, chronic levetiracetam treatment suppresses the amyloid accumulation and improves hippocampal dependent spatial memory (Sanchez et al., 2012) . However, levetiracetam has multiple plausible molecular targets including voltage-gated ion currents, synaptic vesicle proteins and the glutaminergic system (Surges et al., 2008) , and it is not known which ones are relevant for alleviating AD symptoms.
To investigate these questions, we In combination, our results indicate that reduced firing rates of cortical pyramidal cells emerge as a symptom of amyloid pathology and that reducing inhibition might be a viable approach to improve brain function in AD.
Material and Methods

Animals
For the present study we used male 
Surgical preparation for headfixed electrophysiological recordings
Animals were anesthetized using isoflurane (0.8 -1 l/min, 1.5-2 %). and placed in a stereotaxic frame. At the onset of anesthesia, all mice received subcutaneous injections of carprofen (5 mg/kg) as well as a subcutaneous lidocaine injection through the scalp. The animals' temperature was maintained stable for the duration of the surgical procedure using a heating blanket. The level of anesthesia was checked during operation by pedal reflex. We exposed the skull and inserted a skull screw over the cerebellum to serve as combined reference and ground. We then placed a custom made, circular headplate for head-fixation evenly on the skull and fixated it with dental cement (Super-Bond C&B, Sun Medical, Shiga, Japan). A small craniotomy was drilled over left frontal cortex at +1.78mm anterior and 0.4 mm lateral to bregma and the exposed skull was covered with a silicone elastomer until the first recording. All mice were given at least 2 days to recover from the surgery.
Electrophysiological recordings in frontal cortex of head-fixed mice
The head-fixation setup consisted of two rods that were screwed onto either side of the implanted head-plate and fixated the mice in place on top of a Styrofoam ball that functioned as an air-supported spherical treadmill and allowed us to read out the movement of the animals in a subset of recording sessions. All animals were slowly habituated to head-fixation by placing them in the setup for 3 sessions of 10 minutes for two days prior to the first recording day.
Two hours prior to each recording session, we injected the animals with either 200 mg/kg i.p. levetiracetam, (Sigma-Aldrich, Taufkirchen, Germany), a dose shown to reduce abnormal hyperactivity EEG effectively, or saline (Doheny et al., 1999; Sanchez et al., 2012) . We then alternated these injections for 4 consecutive days to be able to record two sessions per animal and condition (Doheny et al., 1999) . The experimenter was blind to both the genotype as well as to the type of injection. were cut with a freezing slide microtome.
Every second section containing track from the recording electrode were stained for the N-terminal human Aβ-specific antibody W02 (Genetics, Switzerland) to visualize diffuse amyloid deposits as described previously (Hooijmans et al., 2007) to verify the amyloid pathology in the transgenic animals (Fig. 1.) . Additionally, we performed cresyl-violet staining to verify the anterior-posterior coordinates of the recording sites. For each unit we then computed the peakto-peak amplitude of the action potential waveforms as well as the width at 30% of the negative peak. We fed these values into Gaussian-mixture model to classify single units into putative interneurons with narrower spike waveforms and putative pyramidal cells with broader spike waveform (see Fig. 3 for cut off criteria) (Stark et al., 2013) . For each unit, we computed the mean firing rate over the 10min recording sessions and performed a 3factorial ANOVA with neuron type, genotype and drug condition as independent variables, followed by posthoc t-tests wherever justified by significant main or interaction effects.
Additionally, we computed the spike-time cross-correlations between all simultaneously recorded neurons in our experiment and performed the same statistical analysis as above (Moore et al., 1966; Perkel et al., 1967a Perkel et al., , 1967b (Gurevicius et al., 2013; Jin et al., 2018) .
Therefore, we recorded a total of 1705 individual neurons from the frontal cortex of APP/PS1 mice under various conditions. Surprisingly, we found that APP/PS1 mice showed overall reduced firing rates compared to the wildtype controls (t-test, p = 0.011).
To further investigate whether this effect was specific to a certain neuron type, we classified the recorded single cells as either putative pyramidal cells or interneurons according to their action potential waveform (Stark et al., 2013) . This analysis revealed that the amyloid pathology related reduction of firing rates in APP/PS1 mice was specific to putative pyramidal increase in mean firing rates ( Fig. 3C . and Fig. 4A.) . We found that the overall more sparsely firing pyramidal cells in APP/PS1 mice were significantly more phase-locked to the ongoing theta and beta oscillation than in wild type controls (theta: Wilcoxon Rank sum test, p<0.001 (Fig. 5B.) ; beta: Wilcoxon Rank sum test, p<0.001 (Fig. 6A.) ; n=228
(WT/Pyr); 386 (APP/PS1/Pyr)) Phase locking in the gamma range between 30-100 Hz was not significantly affected ( Fig.   6B.) .
Levetiracetam restore reduced firing
rates of single neurons in frontal cortex of APP/PS1 mice Interestingly, we found that levetiracetam specifically elevated firing rates in frontal cortex neurons in APP/PS1 mice ( Fig. 7 . and Levetiracetam therefore specifically reversed the perturbing effect of amyloid pathology on pyramidal cells in APP/PS1 mice.
Levetiracetam uncouples pyramidal cells and interneurons in APP/PS1 mice
Levetiracetam has been shown to suppress vesicle release (De Smedt et al., 2007a; Surges et al., 2008; Vogl et al., 2012) . interneurons + sal p< 0.001).
Discussion
In line with previous studies , we found that LFP power was increased in 9-month-old APP/PS1 mice in the theta and beta frequency bands between 6 and 26 Hz (Gurevicius et al., 2013; Jin et al., 2018) .
However, contrary to the prevailing interpretation that increased LFP power indicates hyperactivity on the single cell level in AD mouse models, we found that firing rates, specifically of frontal cortical pyramidal cells, were significantly reduced in APP/PS1 mice compared to wildtype controls (Jiruska et al., 2013) . One explanation for these counterintuitive results was our finding that phase-locking of pyramidal cells to the dominant cortical theta and beta oscillations increases and that this can lead to an increase in LFP power. Interestingly, it has been shown previously that GABA levels in frontal cortex of AD mice can rise continuously and peak around 9 months of age, the same age as our cohort (Roy et al., 2018) . Therefore, one plausible interpretation of our results is that increased cortical inhibition in APP/PS1 mice leads to a narrower window of opportunity for pyramidal cell spiking.
While this would need to be verified in our model, pathologically increased cortical inhibition could explain overall decreased firing rates as well as the more precise alignment of spikes with the ongoing theta and beta oscillations.
Acute systemic injection of levetiracetam reversed the effects of AD pathophysiology and specifically restored pyramidal cell firing rates back to control levels.
Levetiracetam is commonly used to treat neuronal hyperactivity during epileptic seizures (Cumbo and Ligori, 2010; De Smedt et al., 2007b) . Therefore, it seems unlikely to us that levetiracetam directly acts in an excitatory way on pyramidal neurons. Furthermore, it has been shown previously that levetiracetam reduces vesicle release from presynaptic terminals (Vogl et al., 2012) . Therefore, we assume Targeting inhibitory transmission in AD therefore seems to us as a viable new route to potentially reverse network dysfunction in AD.
